- Protein-Tyrosine Kinases
- Accession Number
Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors.
Drug Drug Description Nelipepimut-S Investigated for use/treatment in prostate cancer and breast cancer. VEGFR2-169 VEGFR2-169 is under investigation in clinical trial NCT00655785 (Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2)).
- Drugs & Drug Targets
Drug Target Type Nelipepimut-S HLA class I histocompatibility antigen, A-2 alpha chain target Nelipepimut-S HLA class I histocompatibility antigen, A-3 alpha chain target